Market Cap 1.30B
Revenue (ttm) 277.25M
Net Income (ttm) 27.31M
EPS (ttm) N/A
PE Ratio 38.48
Forward PE N/A
Profit Margin 9.85%
Debt to Equity Ratio 0.08
Volume 1,331,600
Avg Vol 1,664,848
Day's Range N/A - N/A
Shares Out 117.43M
Stochastic %K 76%
Beta 1.09
Analysts Sell
Price Target $21.00

Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccin...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 510 848 5100
Fax: 510 848 1327
Address:
2100 Powell Street, Suite 720, EmeryVille, United States
amessagefromtheodd
amessagefromtheodd Nov. 17 at 2:57 AM
$DVAX The resolve for no surveillance is the COVID oral pill: https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON572
1 · Reply
JeffTex
JeffTex Nov. 16 at 10:45 PM
$DVAX not looking good for those of us hoping for the Nov pump up to $14-$15 so we can bail
0 · Reply
doro987doro987
doro987doro987 Nov. 16 at 9:24 PM
$VXRT P5. Dynavax ($DVAX) – Why they spent $30M? This is important. The Dynavax deal is NOT a bet on COVID. It’s a strategic bet on NORO + the platform, with asymmetric risk/return. Here’s why: ✔ DVAX wants new revenue streams HEPLISAV-B is a solid product, but DVAX needs pipeline diversification. NORO is one of the biggest untapped vaccine markets in the world. ✔ Vaxart’s oral delivery = zero competition No one else has a serious oral NORO vaccine program. If it works, DVAX gets: a high-margin asset differentiation no big pharma currently has first-mover advantage in a multi-billion market
1 · Reply
KWalzz
KWalzz Nov. 15 at 9:01 AM
$DVAX here is when Deep Track exactly sold at what share price, but this was known out from the Form 4 which I posted by then. just interesting to see what big insts think about the share price this co trades at, 10-11 seems right valued to them for now.
0 · Reply
KWalzz
KWalzz Nov. 15 at 8:51 AM
$DVAX here the real and correct update on insts holdings: Deep Track sold more than 2,000,000 shares in their last reported Q. Almost all insts sold while a hedge fund added nearly 3m shares. Millennium is not generally regarded as biotech specialists but is well known for high-frequency trading, systematic market strategies, and leveraging both long and short positions to generate returns, which does connect them to short-selling. Millennium is often viewed as a "shark-like" hedge fund due to its aggressive, risk-controlled, and opportunistic trading style. Let's see what this will bring to DVAX share trading. I fear not the best. DVAX should really have focused on its core business and made more for shareholders, it is very late now if not too late.
0 · Reply
RoyalEclipse
RoyalEclipse Nov. 15 at 6:14 AM
0 · Reply
RoutineMidnight5779
RoutineMidnight5779 Nov. 15 at 6:01 AM
$VXRT $DVAX Does Dynavax’s stake increase the chance of a future buyout? Yes. Significantly. Here’s why: They now have a financial incentive If the pill works, DVAX wants: Revenues Royalties Control of commercialization Elimination of licensing costs Full ownership of a mucosal vaccine platform They are now deeply invested (emotionally and financially) 11.1M shares + $25M upfront investment is meaningful for a company like DVAX. They positioned themselves EARLY This is exactly how strategic buyouts start: 1. Partnership 2. Small equity position 3. Development control 4. Option to take full commercial ownership 5. Buyout if Phase 2b data justifies it DVAX acquiring VXRT eliminates future royalty payments Instead of paying: $50M $195M $425M Royalties DVAX could buy Vaxart outright for far cheaper if they strike before Phase 3.
3 · Reply
RoutineMidnight5779
RoutineMidnight5779 Nov. 15 at 5:58 AM
$VXRT $DVAX DVAX wants Vaxart on an upward trajectory They want: Strong Phase 2b Their $5M equity to rise Their option value ($50M) to become commercially attractive Potential future buyout math to look good Reverse splits hurt all those goals.
0 · Reply
RoutineMidnight5779
RoutineMidnight5779 Nov. 15 at 5:55 AM
$VXRT $DVAX Why DVAX wouldn't like a reverse split: 1. Reverse splits historically destroy shareholder value Biotech reverse splits ≈ automatic 20–40% drop afterward. 2. Dynavax wants their 11.1M shares to APPRECIATE A split would cut those shares: 1-for-10 → DVAX goes from 11.1M shares → 1.1M shares Still worth same $ amount technically, but Market almost always sells off → DVAX loses money 3. DVAX is a profitable, disciplined company They don’t invest to gamble—they invest for strategic upside. Reverse splits signal desperation, not strength.
0 · Reply
RoutineMidnight5779
RoutineMidnight5779 Nov. 15 at 5:52 AM
$VXRT $DVAX Dynavax is now Vaxart’s largest shareholder AND its development/commercialization partner. That’s why the market should have reacted stronger — but because most investors haven’t put these pieces together yet (and the OTC status hides this), it's being slept on.
0 · Reply
Latest News on DVAX
3 Of My Favorite Biotech Stocks Under $10

Sep 29, 2025, 1:15 PM EDT - 6 weeks ago

3 Of My Favorite Biotech Stocks Under $10

FOLD MRNA NUVB PFE


Dynavax Technologies: A Dip To Accumulate

Aug 11, 2025, 8:41 AM EDT - 3 months ago

Dynavax Technologies: A Dip To Accumulate


Dynavax Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:00 PM EDT - 3 months ago

Dynavax Reports Second Quarter 2025 Financial Results


Dynavax Comments on Glass Lewis Recommendation

Jun 4, 2025, 4:59 PM EDT - 5 months ago

Dynavax Comments on Glass Lewis Recommendation


Deep Track Capital Comments on ISS Recommendation

May 23, 2025, 6:12 PM EDT - 6 months ago

Deep Track Capital Comments on ISS Recommendation


Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good

May 21, 2025, 11:48 PM EDT - 6 months ago

Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good


Dynavax Files Preliminary Proxy Statement

Apr 3, 2025, 5:40 PM EDT - 8 months ago

Dynavax Files Preliminary Proxy Statement


Dynavax to Participate in Upcoming Investor Conferences

Feb 25, 2025, 4:10 PM EST - 9 months ago

Dynavax to Participate in Upcoming Investor Conferences


Dynavax Advances Board Refreshment Program

Jan 27, 2025, 6:00 AM EST - 10 months ago

Dynavax Advances Board Refreshment Program


amessagefromtheodd
amessagefromtheodd Nov. 17 at 2:57 AM
$DVAX The resolve for no surveillance is the COVID oral pill: https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON572
1 · Reply
JeffTex
JeffTex Nov. 16 at 10:45 PM
$DVAX not looking good for those of us hoping for the Nov pump up to $14-$15 so we can bail
0 · Reply
doro987doro987
doro987doro987 Nov. 16 at 9:24 PM
$VXRT P5. Dynavax ($DVAX) – Why they spent $30M? This is important. The Dynavax deal is NOT a bet on COVID. It’s a strategic bet on NORO + the platform, with asymmetric risk/return. Here’s why: ✔ DVAX wants new revenue streams HEPLISAV-B is a solid product, but DVAX needs pipeline diversification. NORO is one of the biggest untapped vaccine markets in the world. ✔ Vaxart’s oral delivery = zero competition No one else has a serious oral NORO vaccine program. If it works, DVAX gets: a high-margin asset differentiation no big pharma currently has first-mover advantage in a multi-billion market
1 · Reply
KWalzz
KWalzz Nov. 15 at 9:01 AM
$DVAX here is when Deep Track exactly sold at what share price, but this was known out from the Form 4 which I posted by then. just interesting to see what big insts think about the share price this co trades at, 10-11 seems right valued to them for now.
0 · Reply
KWalzz
KWalzz Nov. 15 at 8:51 AM
$DVAX here the real and correct update on insts holdings: Deep Track sold more than 2,000,000 shares in their last reported Q. Almost all insts sold while a hedge fund added nearly 3m shares. Millennium is not generally regarded as biotech specialists but is well known for high-frequency trading, systematic market strategies, and leveraging both long and short positions to generate returns, which does connect them to short-selling. Millennium is often viewed as a "shark-like" hedge fund due to its aggressive, risk-controlled, and opportunistic trading style. Let's see what this will bring to DVAX share trading. I fear not the best. DVAX should really have focused on its core business and made more for shareholders, it is very late now if not too late.
0 · Reply
RoyalEclipse
RoyalEclipse Nov. 15 at 6:14 AM
0 · Reply
RoutineMidnight5779
RoutineMidnight5779 Nov. 15 at 6:01 AM
$VXRT $DVAX Does Dynavax’s stake increase the chance of a future buyout? Yes. Significantly. Here’s why: They now have a financial incentive If the pill works, DVAX wants: Revenues Royalties Control of commercialization Elimination of licensing costs Full ownership of a mucosal vaccine platform They are now deeply invested (emotionally and financially) 11.1M shares + $25M upfront investment is meaningful for a company like DVAX. They positioned themselves EARLY This is exactly how strategic buyouts start: 1. Partnership 2. Small equity position 3. Development control 4. Option to take full commercial ownership 5. Buyout if Phase 2b data justifies it DVAX acquiring VXRT eliminates future royalty payments Instead of paying: $50M $195M $425M Royalties DVAX could buy Vaxart outright for far cheaper if they strike before Phase 3.
3 · Reply
RoutineMidnight5779
RoutineMidnight5779 Nov. 15 at 5:58 AM
$VXRT $DVAX DVAX wants Vaxart on an upward trajectory They want: Strong Phase 2b Their $5M equity to rise Their option value ($50M) to become commercially attractive Potential future buyout math to look good Reverse splits hurt all those goals.
0 · Reply
RoutineMidnight5779
RoutineMidnight5779 Nov. 15 at 5:55 AM
$VXRT $DVAX Why DVAX wouldn't like a reverse split: 1. Reverse splits historically destroy shareholder value Biotech reverse splits ≈ automatic 20–40% drop afterward. 2. Dynavax wants their 11.1M shares to APPRECIATE A split would cut those shares: 1-for-10 → DVAX goes from 11.1M shares → 1.1M shares Still worth same $ amount technically, but Market almost always sells off → DVAX loses money 3. DVAX is a profitable, disciplined company They don’t invest to gamble—they invest for strategic upside. Reverse splits signal desperation, not strength.
0 · Reply
RoutineMidnight5779
RoutineMidnight5779 Nov. 15 at 5:52 AM
$VXRT $DVAX Dynavax is now Vaxart’s largest shareholder AND its development/commercialization partner. That’s why the market should have reacted stronger — but because most investors haven’t put these pieces together yet (and the OTC status hides this), it's being slept on.
0 · Reply
RoutineMidnight5779
RoutineMidnight5779 Nov. 15 at 5:45 AM
$VXRT $DVAX I don't believe the largest shareholder of Vaxart would be pleased with an R/S by Vaxart cutting their investment in half. Dynavax has good fundamentals, this is a strong investment movement. Dynavac is looking for profit and opportunity for growth. This is Bullish and people don't even know it.
0 · Reply
RoutineMidnight5779
RoutineMidnight5779 Nov. 15 at 5:43 AM
$VXRT $DVAX If Dynavax owns 11,111,111 shares of Vaxart doesn't that make them the largest share holder?
0 · Reply
AccuRoger
AccuRoger Nov. 14 at 10:39 PM
$DVAX The FinTel website provides an update on the behavior of Institutions as of September 30. Goldman Sachs increased their shares held long by 13% to 1.8 million shares. They also set a PUT option on 225k shares at the SAME TIME! They advise the debt holders while also managing the $300 million share buyback program. They are NOT on the side of Retail Investors. You pays y’re money and takes y’re chances. DeepTrack attempted to add a couple of members to the BOD and were rejected by shareholders in April. They reported the following data in August and repeated this same amount for the end of Q3. What does it mean? Institutions are still large and in charge here despite nine of the top 10 holders reducing their shares held long in Q3 (at $9.20-$12.05 per share). They play the volatility Long and Short (learn about DELTA and hedging) in a manner that meets THEIR risk and tax priorities. Therefore, shaking your virtual fist at them does not inform your investment decisions.
0 · Reply
KWalzz
KWalzz Nov. 14 at 3:45 PM
$DVAX I wish that Deep Track and other big insts cooperate in removing these clowns. They just laugh at shareholders anymore, there is nothing left that can be seen as serious here except the sale of Heplisav. Deep Track was absolutely right in EVERY RESPECT !! Now there is this so-called deal about an oral pill that will never be approved (chance for approval is around 0.05% compared to normal vaccs) which is just mockery ... they need to be REMOVED once and for all.
1 · Reply
amessagefromtheodd
amessagefromtheodd Nov. 14 at 3:36 PM
$VXRT If COVID data is Good, Very Good or Remarkable and $DVAX moves forward with escalating commercialization of their COVID pill or if they don’t with still the three choices above, than a poor man’s garbage is rich men treasures. I doubt it will be left on the table, which ever way it goes…
1 · Reply
JeffTex
JeffTex Nov. 14 at 2:42 PM
$DVAX CDTX I mentioned a few weeks ago just more than doubled to $217 on buyout from Merck. A little over a year ago it was $15 share.
0 · Reply
RoutineMidnight5779
RoutineMidnight5779 Nov. 13 at 9:56 PM
$VXRT $DVAX looking to partner for norovirus also?
2 · Reply
RoutineMidnight5779
RoutineMidnight5779 Nov. 13 at 9:34 PM
$VXRT $DVAX VAXART conference call. Come join us Dynavax.
0 · Reply
KWalzz
KWalzz Nov. 13 at 3:59 PM
$DVAX all biggies (reported) reduced last Q ... congratulations Spencer🤡 & Myers🤡 !! this is your way to create shareholder value.🫣
1 · Reply
LUCKY_Cool_Cat
LUCKY_Cool_Cat Nov. 12 at 11:32 PM
@Buy_dvax100 $DVAX You look like the only retail investor here. Any information on who holds stock?
3 · Reply
KWalzz
KWalzz Nov. 12 at 4:32 PM
$DVAX SI update: down a bit.
1 · Reply
Buy_dvax100
Buy_dvax100 Nov. 12 at 2:47 PM
$DVAX 🚀
0 · Reply